首页 | 本学科首页   官方微博 | 高级检索  
     


Early prediction of clinical response in first episode schizophrenia (FES) patients receiving olanzapine
Authors:Viswam Subeesh  Eswaran Maheswari  Hemendra Singh  Ganesan Rajalekshmi Saraswathy  Neha Reddy  Pudi Chiranjeevi
Affiliation:1. Department of Pharmacy Practice, Faculty of Pharmacy, M S Ramaiah University of Applied Sciences, Bengaluru, India;2. subeeshkviswam@gmail.com subeesh.pp.ph@msruas.ac.in"ORCIDhttps://orcid.org/0000-0002-1721-4553;4. Department of Psychiatry, Ramaiah Medical College, Bengaluru, India
Abstract:Abstract

Background: At present, schizophrenia guidelines recommend waiting for 8?weeks before considering a patient as non-responder. This study aims to detect the optimal early response threshold that best predict the final outcome of olanzapine.

Methods: The study was conducted for 8-week, four points follow up (week 2,3,4, and 8) prospective observational study. A reduction of 20, 25, 30% in Positive and Negative Syndrome Scale (PANSS) score from the base line at week 2,3, and 4 respectively were considered as early response. A reduction of 50% at week 8 was considered as responders. Receiver Operating Characteristics (ROC) curves were performed to detect the optimal threshold.

Results: Mean total baseline PANSS score was 106.66(95% CI; 100.4, 112.9). Week 2 (AUC = 50.5%, p?>?0.964) and week 3 (AUC = 64.9, p?>?0.13) responses failed to predict the 8th week response. Week 4 response (AUC = 92%, p?Conclusions: Our study suggests that patients with early response at week 4 are likely to achieve positive response after 8?weeks. This may help in appropriate clinical decision making for early non-responders.
  • Key Points
  • The early response can forecast the outcome at the endpoint for the treatment of FES

  • A reduction of baseline PANSS score by 30% or more after four weeks are likely to have remission after week 8 with olanzapine therapy.

Keywords:Schizophrenia  early response  olanzapine  PANSS
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号